After a proof-of-concept clinical trial failed to meet its main goal, Immunovant announced that it will not pursue further development of its experimental therapy IMVT-1402 (imeroprubart) as a treatment for cutaneous lupus erythematosus (CLE). Immunovant sponsored a Phase 2 study (NCT06980805) that compared IMVT-1402 with a placebo…
News
The Lupus Research Alliance (LRA) has announced more than $2 million in funding for three new pilot projects that focus on innovative lifestyle interventions — from supplements to physical exercise — for people with lupus. The research teams behind each project will receive up to $750,000 over three…
Participants are actively being recruited for a pair of Phase 3 clinical trials testing enpatoran, an experimental oral medication designed to treat skin manifestations of lupus. The identically designed ELOWEN studies aim to enroll more than 400 adults ages 18 to 75 with skin manifestations of lupus, with or…
Disruption of a natural process called X-chromosome inactivation (XCI) in immune B-cells — occurring when one X chromosome in females is turned off during development — may directly contribute to the development of systemic lupus erythematosus (SLE), two new studies led by a veterinary professor suggest. According to Montserrat…
The Lupus Research Alliance and Genentech have launched a new funding program to support three research projects focused on developing immune-resetting CAR T-cell therapies for lupus. The initiative seeks to deepen the scientific understanding of how these treatments work…
The U.S. Food and Drug Administration (FDA) has approved a self-injected version of Saphnelo (anifrolumab-fnia). Like the original version of Saphnelo, which is given by infusion into the bloodstream every four weeks, the Saphnelo Pen is indicated for use in combination with standard therapy for systemic lupus erythematosus…
This May, organizations will mark Lupus Awareness Month with initiatives and are calling on the lupus community to take action to spread the word. Observed each year, the campaign also includes Lupus Awareness Day on May 10, a key moment to spotlight the challenges faced by people living with…
A combination of two simple lab tests may provide a noninvasive, more reliable way to assess disease activity in systemic lupus erythematosus (SLE) — the most common form of the autoimmune disorder lupus — and detect early kidney involvement, a study suggested. Researchers found that blood levels of galectin-9,…
Biogen is making “strong progress” with enrollment in the AMETHYST study, a Phase 2/3 clinical trial testing the company’s experimental therapy litifilimab (BIIB059) in people with cutaneous lupus erythematosus (CLE). That’s according to Diana Gallagher, MD, Biogen’s…
An under-the-skin, self-administered version of Saphnelo (anifrolumab-fnia) could soon allow people with systemic lupus erythematosus (SLE) to manage their condition at home with the same effectiveness as clinical infusions. According to AstraZeneca, the new subcutaneous formulation provides efficacy comparable to the approved intravenous formulation while significantly reducing the…
Recent Posts
- Experimental skin lupus therapy dropped after trial misses main goal
- When we’re too sick to work, but not sick enough for disability
- Embracing an earworm song can benefit those of us with lupus
- Alliance awards over $2M for lifestyle intervention studies in lupus
- Understanding the grief of chronic illness has made me more self-aware